Location via proxy:   [ UP ]  
[Report a bug]   [Manage cookies]                
Skip to main content
Springer Nature Link
Log in

Comparisons of CYP1A2 genetic polymorphisms, enzyme activity and the genotype-phenotype relationship in Swedes and Koreans

  • Pharmacogenetics
  • Published:
European Journal of Clinical Pharmacology Aims and scope Submit manuscript

Abstract

Objectives

To investigate the CYP1A2 genotype-phenotype relationship and to compare CYP1A2 genetic polymorphisms and enzyme activity in terms of the effect of smoking and oral contraceptive (OC) use in Swedes and Koreans.

Methods

CYP1A2 enzyme activity was determined in 194 and 150 healthy Swedish and Korean subjects, respectively, on the basis of the 4-h plasma paraxanthine/caffeine (17X/137X) ratio determined using high-performance liquid chromatography. Genotyping for the −3860G>A, −2467delT, −739 T>G, −729 C>T, −163C>A and −3113A>G polymorphisms was performed by PCR-restriction fragment length polymorphism analysis.

Results

The mean 17X/137X ratio was 1.54-fold higher in Swedes than in Koreans (mean difference: 0.16; 95% CI of the mean difference: 0.12, 0.20; p < 0.0001). Smokers had a significantly higher 17X/137X ratio (higher CYP1A2 activity) than non-smokers, while Swedish OC users had a significantly lower 17X/137X ratio than non-users (mean difference: 0.31, 95% CI of the mean difference: 0.23, 0.39; p < 0.0001). No effect of gender differences on enzyme activity was observed. Four known (CYP1A2*1A, *1D, *1F, and *1L) and two novel haplotypes (CYP1A2*1V and CYP1A2*1W) were found. CYP1A2*1K was rare in Swedes and absent in Koreans. No significant genotype-phenotype relationship was observed, with the exception of CYP1A2*1F in Swedish smokers, where it was associated with higher enzyme inducibility (p = 0.02). Koreans displayed a significantly lower mean 17X/137X ratio than Swedes having the same CYP1A2 genotype, smoking habit and OC use.

Conclusions

We found significant differences in CYP1A2 enzyme activity between Swedes and Koreans that could not be explained by environmental factors or the CYP1A2 haplotypes examined, despite differences in allele frequencies. None of the investigated CYP1A2 haplotypes are critical in inducing variations in enzyme activity, with the exception of CYP1A2*1F.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Subscribe and save

Springer+ Basic
$34.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or eBook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Shimada T, Yamazaki H, Mimura M, Inui Y, Guengerich FP (1994) Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 Caucasians. J Pharmacol Exp Ther 270:414–423

    PubMed  CAS  Google Scholar 

  2. Bertilsson L, Carrillo JA, Dahl ML, Llerena A, Alm C, Bondesson U, Lindstrom L, Rodriguez de la Rubia I, Ramos S, Benitez J (1994) Clozapine disposition covaries with CYP1A2 activity determined by a caffeine test. Br J Clin Pharmacol 38:471–473

    PubMed  CAS  Google Scholar 

  3. Kroemer HK, Gautier JC, Beaune P, Henderson C, Wolf CR, Eichelbaum M (1993) Identification of P450 enzymes involved in metabolism of verapamil in humans. Naunyn Schmiedebergs Arch Pharmacol 348:332–337

    Article  PubMed  CAS  Google Scholar 

  4. Hartter S, Ursing C, Morita S, Tybring G, von Bahr C, Christensen M, Rojdmark S, Bertilsson L (2001) Orally given melatonin may serve as a probe drug for cytochrome P450 1A2 activity in vivo: a pilot study. Clin Pharmacol Ther 70:10–16

    Article  PubMed  CAS  Google Scholar 

  5. Yamazaki H, Shaw PM, Guengerich FP, Shimada T (1998) Roles of cytochromes P450 1A2 and 3A4 in the oxidation of estradiol and estrone in human liver microsomes. Chem Res Toxicol 11:659–665

    Article  PubMed  CAS  Google Scholar 

  6. Carrillo JA, Christensen M, Ramos SI, Alm C, Dahl ML, Benitez J, Bertilsson L (2000) Evaluation of caffeine as an in vivo probe for CYP1A2 using measurements in plasma, saliva, and urine. Ther Drug Monit 22:409–417

    Article  PubMed  CAS  Google Scholar 

  7. Kalow W, Tang BK (1991) Caffeine as a metabolic probe: exploration of the enzyme-inducing effect of cigarette smoking. Clin Pharmacol Ther 49:44–48

    Article  PubMed  CAS  Google Scholar 

  8. Rasmussen BB, Brix TH, Kyvik KO, Brosen K (2002) The interindividual differences in the 3-demethylation of caffeine alias CYP1A2 is determined by both genetic and environmental factors. Pharmacogenetics 12:473–478

    Article  PubMed  CAS  Google Scholar 

  9. Abernethy DR, Todd EL (1985) Impairment of caffeine clearance by chronic use of low-dose oestrogen-containing oral contraceptives. Eur J Clin Pharmacol 28:425–428

    Article  PubMed  CAS  Google Scholar 

  10. Conney AH, Pantuck EJ, Hsiao KC, Garland WA, Anderson KE, Alvares AP, Kappas A (1976) Enhanced phenacetin metabolism in human subjects fed charcoal-broiled beef. Clin Pharmacol Ther 20:633–642

    PubMed  CAS  Google Scholar 

  11. Aklillu E, Carrillo JA, Makonnen E, Hellman K, Pitarque M, Bertilsson L, Ingelman-Sundberg M (2003) Genetic polymorphism of CYP1A2 in Ethiopians affecting induction and expression: characterization of novel haplotypes with single-nucleotide polymorphisms in intron 1. Mol Pharmacol 64:659–669

    Article  PubMed  CAS  Google Scholar 

  12. Nakajima M, Yokoi T, Mizutani M, Kinoshita M, Funayama M, Kamataki T (1999) Genetic polymorphism in the 5′-flanking region of human CYP1A2 gene: effect on the CYP1A2 inducibility in humans. J Biochem 125:803–808

    PubMed  CAS  Google Scholar 

  13. Sachse C, Brockmoller J, Bauer S, Roots I (1999) Functional significance of a C->A polymorphism in intron 1 of the cytochrome P450 CYP1A2 gene tested with caffeine. Br J Clin Pharmacol 47:445–449

    Article  PubMed  CAS  Google Scholar 

  14. Allorge D, Chevalier D, Lo-Guidice JM, Cauffiez C, Suard F, Baumann P, Eap CB, Broly F (2003) Identification of a novel splice-site mutation in the CYP1A2 gene. Br J Clin Pharmacol 56:341–344

    Article  PubMed  CAS  Google Scholar 

  15. Chida M, Yokoi T, Fukui T, Kinoshita M, Yokota J, Kamataki T (1999) Detection of three genetic polymorphisms in the 5′-flanking region and intron 1 of human CYP1A2 in the Japanese population. Jpn J Cancer Res 90:899–902

    PubMed  CAS  Google Scholar 

  16. Nordmark A, Lundgren S, Ask B, Granath F, Rane A (2002) The effect of the CYP1A2 *1F mutation on CYP1A2 inducibility in pregnant women. Br J Clin Pharmacol 54:504–510

    Article  PubMed  CAS  Google Scholar 

  17. Shimoda K, Someya T, Morita S, Hirokane G, Yokono A, Takahashi S, Okawa M (2002) Lack of impact of CYP1A2 genetic polymorphism (C/A polymorphism at position 734 in intron 1 and G/A polymorphism at position −2964 in the 5′-flanking region of CYP1A2) on the plasma concentration of haloperidol in smoking male Japanese with schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 26:261–265

    Article  PubMed  CAS  Google Scholar 

  18. Larsen JT, Brosen K (2005) Consumption of charcoal-broiled meat as an experimental tool for discerning CYP1A2-mediated drug metabolism in vivo. Basic Clin Pharmacol Toxicol 97:141–148

    Article  PubMed  CAS  Google Scholar 

  19. Chen X, Wang L, Zhi L, Zhou G, Wang H, Zhang X, Hao B, Zhu Y, Cheng Z, He F (2005) The G-113A polymorphism in CYP1A2 affects the caffeine metabolic ratio in a Chinese population. Clin Pharmacol Ther 78:249–259

    Article  PubMed  CAS  Google Scholar 

  20. Murayama N, Soyama A, Saito Y, Nakajima Y, Komamura K, Ueno K, Kamakura S, Kitakaze M, Kimura H, Goto Y, Saitoh O, Katoh M, Ohnuma T, Kawai M, Sugai K, Ohtsuki T, Suzuki C, Minami N, Ozawa S, Sawada J (2004) Six novel nonsynonymous CYP1A2 gene polymorphisms: catalytic activities of the naturally occurring variant enzymes. J Pharmacol Exp Ther 308:300–306

    Article  PubMed  CAS  Google Scholar 

  21. Chevalier D, Cauffiez C, Allorge D, Lo-Guidice JM, Lhermitte M, Lafitte JJ, Broly F (2001) Five novel natural allelic variants-951A>C, 1042G>A (D348N), 1156A>T (I386F), 1217G>A (C406Y) and 1291C>T (C431Y)-of the human CYP1A2 gene in a French Caucasian population. Hum Mutat 17:355–356

    Google Scholar 

  22. Christensen M, Andersson K, Dalen P, Mirghani RA, Muirhead GJ, Nordmark A, Tybring G, Wahlberg A, Yasar U, Bertilsson L (2003) The Karolinska cocktail for phenotyping of five human cytochrome P450 enzymes. Clin Pharmacol Ther 73:517–528

    Article  PubMed  CAS  Google Scholar 

  23. Arlequin (2000) Arlequin: a software for population genetics data analysis, ver. 2.000. Genetics and Biometry Laboratory, Department of Anthropology, University of Geneva, Geneva, Switzerland

  24. Kall MA, Clausen J (1995) Dietary effect on mixed function P450 1A2 activity assayed by estimation of caffeine metabolism in man. Hum Exp Toxicol 14:801–807

    Article  PubMed  CAS  Google Scholar 

  25. Todesco L, Torok M, Krahenbuhl S, Wenk M (2003) Determination of −3858G−>A and −164C−>A genetic polymorphisms of CYP1A2 in blood and saliva by rapid allelic discrimination: large difference in the prevalence of the −3858G−>A mutation between Caucasians and Asians. Eur J Clin Pharmacol 59:343–346

    Article  PubMed  CAS  Google Scholar 

  26. Takata K, Saruwatari J, Nakada N, Nakagawa M, Fukuda K, Tanaka F, Takenaka S, Mihara S, Marubayashi T, Nakagawa K (2006) Phenotype-genotype analysis of CYP1A2 in Japanese patients receiving oral theophylline therapy. Eur J Clin Pharmacol 62:23–28

    Article  PubMed  CAS  Google Scholar 

  27. Cornelis MC, El-Sohemy A, Kabagambe EK, Campos H (2006) Coffee, CYP1A2 genotype, and risk of myocardial infarction. JAMA 295:1135–1141

    Article  PubMed  CAS  Google Scholar 

  28. Ingelman-Sundberg M, Sim SC, Nebert DW (2006) Coffee, myocardial infarction, and CYP nomenclature. JAMA 296:764–765; author reply 765–766

    Article  PubMed  CAS  Google Scholar 

  29. Jiang Z, Dragin N, Jorge-Nebert LF, Martin MV, Peter Guengerich F, Aklillu E, Ingelman-Sundberg M, Hammons GJ, Lyn-Cook BD, Kadlubar FF, Saldana SN, Sorter M, Vinks AA, Nassr N, von Richter O, Jin L, Nebert DW (2006) Search for an association between the human CYP1A2 genotype and CYP1A2 metabolic phenotype. Pharmacogenet Genomics 16:359–367

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgment

We thank Birgitta Ask and Jolanta Widen for their excellent technical assistance. The study was supported by the Swedish Research Council, Medicine, 3902, and by NIH (R01 GM60548).

Conflict of interest statement

The authors have identified no conflicts of interest in relation to this manuscript. This study complies with the current laws of Sweden and Korea, where it was performed, inclusive of ethics approvals.

Author information

Authors and Affiliations

  1. Division of Clinical Pharmacology, Karolinska University Hospital-Huddinge, Karolinska Institutet, C1-68, 141 86, Stockholm, Sweden

    Roza Ghotbi, Magnus Christensen, Eleni Aklillu & Leif Bertilsson

  2. Department of Internal Medicine, Division of Clinical Pharmacology, Inha University Hospital, 7-206, 3-Ga, Shinheung-Dong, Jung-Gu, Incheon, 400–711, South Korea

    Hyung-Keun Roh

  3. Section of Pharmacogenetics, Department of Physiology and Pharmacology, Karolinska Institutet, 171 77, Stockholm, Sweden

    Magnus Ingelman-Sundberg

Authors
  1. Roza Ghotbi
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Magnus Christensen
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Hyung-Keun Roh
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Magnus Ingelman-Sundberg
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Eleni Aklillu
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Leif Bertilsson
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Eleni Aklillu.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Ghotbi, R., Christensen, M., Roh, HK. et al. Comparisons of CYP1A2 genetic polymorphisms, enzyme activity and the genotype-phenotype relationship in Swedes and Koreans. Eur J Clin Pharmacol 63, 537–546 (2007). https://doi.org/10.1007/s00228-007-0288-2

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00228-007-0288-2

Keywords

Search

Navigation